ClinVar Miner

Submissions for variant NM_022124.6(CDH23):c.130G>A (p.Glu44Lys) (rs1390133151)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000825884 SCV000967369 uncertain significance not specified 2019-06-18 criteria provided, single submitter clinical testing Variant classified as Uncertain Significance - Favor Pathogenic. The p.Glu44Lys variant in CDH23 has been previously reported in two individuals with clinical features of Usher syndrome type 1, including one heterozygous individual and one individual who carried p.Glu44Lys in the compound heterozygous state with a pathogenic CDH23 variant (Bujakowska 2014, Okano 2019). It has also been identified by our laboratory in one individual with hearing loss and retinal dystrophy who was compound heterozygous for a second variant of uncertain significance in CDH23. This variant has been identified in 0.006% (1/15432) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. In summary, while there is some suspicion for a pathogenic role, the clinical significance of the p.Glu44Lys variant is uncertain. ACMG/AMP Criteria applied: PM2, PM3, PP4.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.